INDIANAPOLIS: Drugmaker Eli Lilly and Company’s SVP and chief communications officer, Kathryn Beiser, has resigned. Beiser ...

The vote clears the way for a proposed multibillion-dollar expansion of the former Nexus Pharmaceuticals facility.

A European regulatory committee has rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over potentially ...

The Indianapolis drugmaker noted that Kisunla ... should get the drugs and how long they might benefit. Shares of Eli Lilly and Co. climbed more than $2 to $823.99 Friday morning.

Indianapolis Zoo and Eli Lilly are part of a push to move medical industry away from using horseshoe crab blood and towards ...

Eli Lilly and Company (NYSE: LLY) today announced that preclinical data for agents targeting SMARCA2 (BRM) and multiple KRAS ...

Eli Lilly and Company (LLY) has expanded its LillyDirect digital healthcare platform to offer connections to independent ...

A European regulatory committee rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over potentially dangerous risks of brain bleeding and swelling. The European Medicines Agency ...

The Indianapolis drugmaker noted that Kisunla ... should get the drugs and how long they might benefit. Shares of Eli Lilly and Co. climbed more than $2 to $823.99 Friday morning.

INDIANAPOLIS — A European regulatory committee rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over potentially dangerous risks of brain bleeding and swelling. The European Medicines ...

The Indianapolis drugmaker noted that Kisunla ... should get the drugs and how long they might benefit. Shares of Eli Lilly and Co. climbed more than $2, to $823.99 each, Friday morning.